IDH1-话题@MedSci - williamhill asia

#IDH1#

22篇内容 | 1555人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2214718, encodeId=37932214e1832, content=<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a> <a href='/topic/show?id=69d73e26148' target=_blank style='color:#2F92EE;'>#去甲基化酶#</a> <a href='/topic/show?id=b7b31165860d' target=_blank style='color:#2F92EE;'>#2-羟基戊二酸#</a>, objectTitle=Science：新研究揭示mIDH1抑制剂激活抗肿瘤免疫反应机制, objectType=article, longId=834332, objectId=ffaf83433287, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20240713/1720834387866_2185383.png, objectUrl=/article/show_article.do?id=ffaf83433287, replyNumber=0, likeNumber=22, createdTime=2024-07-13, rootId=0, userName=williamhill asia 管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2161857, encodeId=de06216185e1e, content=高达50%的<a href='/topic/show?id=e37c83513be' target=_blank style='color:#2F92EE;'>#胆管癌#</a>可能是<a href='/topic/show?id=877631e09af' target=_blank style='color:#2F92EE;'>#分子靶向治疗#</a>的潜在受益者。几项规模较小的临床试验显示了二线以上靶向治疗的潜力。比如<a href='/topic/show?id=5ae0e40125' target=_blank style='color:#2F92EE;'>#FGFR2#</a>、<a href='/topic/show?id=f5d71312e50' target=_blank style='color:#2F92EE;'>#NTRK#</a>、<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>、<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>、<a href='/topic/show?id=e3818e1893' target=_blank style='color:#2F92EE;'>#HER2#</a>等<a href='/topic/show?id=e6924180936' target=_blank style='color:#2F92EE;'>#基因突变#</a>。以及<a href='/topic/show?id=85cd50561c3' target=_blank style='color:#2F92EE;'>#微卫星不稳定性#</a>MSI的情况，这些相关指标的检测也将会为胆管癌患者的精准治疗打下相应的治疗基础。事实上，其它<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>也是一样的，各个不同的肿瘤都应该按这个思路研究一遍，对于象<a href='/topic/show?id=33771982175' target=_blank style='color:#2F92EE;'>#三阴性乳腺癌#</a>，<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a>，<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>，同样如此，williamhill asia 各位会员们，你们如果有兴趣，要尽快研究，这是一个很好的方向，当然，也可以申请<a href='/topic/show?id=ca2e4095eaf' target=_blank style='color:#2F92EE;'>#国家自然科学基金#</a><a href='/topic/show?id=cebd410388c' target=_blank style='color:#2F92EE;'>#国自然基金#</a>, objectTitle=真实数据，高达50%的胆管癌是分子靶向治疗的潜在受益者，有机会活得更好、更长！, objectType=article, longId=794442, objectId=b596e944427e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/busy-reception-in-a-hospital-with-doctors-and-PUPDEB8.jpg, objectUrl=/article/show_article.do?id=b596e944427e, replyNumber=0, likeNumber=131, createdTime=2023-10-10, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b596e944427e, moduleTitle=真实数据，高达50%的胆管癌是分子靶向治疗的潜在受益者，有机会活得更好、更长！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b596e944427e)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1715497, encodeId=97d11e1549757, content=<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>, objectTitle=NEJM：艾伏尼布联合阿扎胞苷治疗IDH1突变AML的3期研究结果公布，患者获益显著, objectType=article, longId=724783, objectId=51e5e2478377, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51e5e2478377, replyNumber=0, likeNumber=101, createdTime=2023-02-21, rootId=0, userName=ms6127405442416114, userId=be6531934024, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51e5e2478377, moduleTitle=NEJM：艾伏尼布联合阿扎胞苷治疗IDH1突变AML的3期研究结果公布，患者获益显著, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=51e5e2478377)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715498, encodeId=a3311e15498ec, content=<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>, objectTitle=Neurology病例：Ollier病中经组织病理学证实的颅内内生软骨瘤/低级别软骨肉瘤和IDH1突变的弥漫性胶质瘤, objectType=article, longId=734545, objectId=f843e3454596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f843e3454596, replyNumber=0, likeNumber=74, createdTime=2022-09-03, rootId=0, userName=ms6127405442416114, userId=be6531934024, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f843e3454596, moduleTitle=Neurology病例：Ollier病中经组织病理学证实的颅内内生软骨瘤/低级别软骨肉瘤和IDH1突变的弥漫性胶质瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f843e3454596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715496, encodeId=90d31e15496b6, content=<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>, objectTitle=Clin Cancer Res：维奈托克+阿扎胞苷可显著改善IDH1/2突变AML患者的预后, objectType=article, longId=295112, objectId=26cf29511217, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26cf29511217, replyNumber=0, likeNumber=87, createdTime=2022-10-13, rootId=0, userName=ms6127405442416114, userId=be6531934024, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26cf29511217, moduleTitle=Clin Cancer Res：维奈托克+阿扎胞苷可显著改善IDH1/2突变AML患者的预后, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=26cf29511217)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715495, encodeId=c7411e1549527, content=<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>, objectTitle=Clin Cancer Res：突变型IDH1/2双重抑制剂Vorasidenib治疗复发/进展胶质瘤的效果, objectType=article, longId=292034, objectId=9c622920349a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c622920349a, replyNumber=0, likeNumber=98, createdTime=2022-06-19, rootId=0, userName=ms6127405442416114, userId=be6531934024, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c622920349a, moduleTitle=Clin Cancer Res：突变型IDH1/2双重抑制剂Vorasidenib治疗复发/进展胶质瘤的效果, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=9c622920349a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715491, encodeId=e9691e15491e3, content=<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>, objectTitle=PNAS：雷公藤变成为靶向药物？有望用于治疗IDH1突变的癌症, objectType=article, longId=205801, objectId=4ba0205801a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ba0205801a7, replyNumber=0, likeNumber=64, createdTime=2021-05-10, rootId=0, userName=ms6127405442416114, userId=be6531934024, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ba0205801a7, moduleTitle=PNAS：雷公藤变成为靶向药物？有望用于治疗IDH1突变的癌症, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=4ba0205801a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715493, encodeId=61321e1549386, content=<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>, objectTitle=Clin Cancer Res：突变型IDH1/2双重抑制剂Vorasidenib治疗复发/进展胶质瘤的效果, objectType=article, longId=215832, objectId=fb1921583209, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb1921583209, replyNumber=0, likeNumber=78, createdTime=2022-06-27, rootId=0, userName=ms6127405442416114, userId=be6531934024, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb1921583209, moduleTitle=Clin Cancer Res：突变型IDH1/2双重抑制剂Vorasidenib治疗复发/进展胶质瘤的效果, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=fb1921583209)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715494, encodeId=013d1e15494db, content=<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>, objectTitle=JAMA Oncol：Ivosidenib (AG-120)可改善经治IDH1突变肝内胆管细胞癌患者的总生存：III期ClarIDHy研究最终OS分析结果, objectType=article, longId=217781, objectId=606a21e7812d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=606a21e7812d, replyNumber=0, likeNumber=98, createdTime=2021-10-08, rootId=0, userName=ms6127405442416114, userId=be6531934024, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=606a21e7812d, moduleTitle=JAMA Oncol：Ivosidenib (AG-120)可改善经治IDH1突变肝内胆管细胞癌患者的总生存：III期ClarIDHy研究最终OS分析结果, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=606a21e7812d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715490, encodeId=af2c1e15490b0, content=<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>, objectTitle=Blood：IDH1突变通过干扰血红素合成和红细胞生成导致髓系发育不良, objectType=article, longId=204135, objectId=6cb1204135c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cb1204135c1, replyNumber=0, likeNumber=73, createdTime=2021-09-18, rootId=0, userName=ms6127405442416114, userId=be6531934024, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cb1204135c1, moduleTitle=Blood：IDH1突变通过干扰血红素合成和红细胞生成导致髓系发育不良, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6cb1204135c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715489, encodeId=05d71e1548921, content=<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>, objectTitle=FDA批准抗肿瘤药物IDH1抑制剂HH2301临床试验, objectType=article, longId=196558, objectId=65c9196558ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65c9196558ff, replyNumber=0, likeNumber=87, createdTime=2020-08-14, rootId=0, userName=ms6127405442416114, userId=be6531934024, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65c9196558ff, moduleTitle=FDA批准抗肿瘤药物IDH1抑制剂HH2301临床试验, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=65c9196558ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715488, encodeId=91731e154887b, content=<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>, objectTitle=Radiology：IDH1突变胶质瘤在超高分辨率3D MR波谱下会有什么发现？, objectType=article, longId=192032, objectId=d5d5192032ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5d5192032ba, replyNumber=0, likeNumber=106, createdTime=2020-10-16, rootId=0, userName=ms6127405442416114, userId=be6531934024, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5d5192032ba, moduleTitle=Radiology：IDH1突变胶质瘤在超高分辨率3D MR波谱下会有什么发现？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d5d5192032ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715492, encodeId=b0501e154920e, content=<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>, objectTitle=Lancet Oncol：Ivosidenib显著改善晚期mIDH1胆管癌患者的生存率, objectType=article, longId=205802, objectId=07772058025d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07772058025d, replyNumber=0, likeNumber=84, createdTime=2021-10-17, rootId=0, userName=ms6127405442416114, userId=be6531934024, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07772058025d, moduleTitle=Lancet Oncol：Ivosidenib显著改善晚期mIDH1胆管癌患者的生存率, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=07772058025d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715487, encodeId=02841e154870f, content=<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>, objectTitle=Blood：DNMT3A和IDH1/2基因突变携带诱导血液恶性肿瘤的发生！, objectType=article, longId=186280, objectId=bf2d1862808c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf2d1862808c, replyNumber=0, likeNumber=97, createdTime=2020-11-24, rootId=0, userName=ms6127405442416114, userId=be6531934024, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf2d1862808c, moduleTitle=Blood：DNMT3A和IDH1/2基因突变携带诱导血液恶性肿瘤的发生！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=bf2d1862808c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715486, encodeId=41d31e1548614, content=<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>, objectTitle=Cell Death & Disease：前列腺癌中PAX5能够诱导IDH1-AS1上调来促进肿瘤的生长, objectType=article, longId=181686, objectId=2bf0181686fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bf0181686fa, replyNumber=0, likeNumber=99, createdTime=2020-06-22, rootId=0, userName=ms6127405442416114, userId=be6531934024, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bf0181686fa, moduleTitle=Cell Death & Disease：前列腺癌中PAX5能够诱导IDH1-AS1上调来促进肿瘤的生长, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=2bf0181686fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715485, encodeId=e24b1e1548514, content=<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>, objectTitle=2019年ESMO：Ivosidenib显著改善晚期mIDH1胆管癌患者的生存率, objectType=article, longId=180572, objectId=59da1805e210, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59da1805e210, replyNumber=0, likeNumber=101, createdTime=2020-04-09, rootId=0, userName=ms6127405442416114, userId=be6531934024, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59da1805e210, moduleTitle=2019年ESMO：Ivosidenib显著改善晚期mIDH1胆管癌患者的生存率, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=59da1805e210)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715484, encodeId=cd5d1e154846c, content=<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>, objectTitle=FDA批准**IDH1抑制剂用于治疗复发或难治性AML, objectType=article, longId=145063, objectId=68c9145063ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68c9145063ea, replyNumber=0, likeNumber=106, createdTime=2019-06-15, rootId=0, userName=ms6127405442416114, userId=be6531934024, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68c9145063ea, moduleTitle=FDA批准**IDH1抑制剂用于治疗复发或难治性AML, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=68c9145063ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715483, encodeId=9ea31e1548372, content=<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>, objectTitle=NEJM：Ivosidenib治疗IDH1突变型AML疗效喜人, objectType=article, longId=139938, objectId=f21013993802, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f21013993802, replyNumber=0, likeNumber=103, createdTime=2018-10-06, rootId=0, userName=ms6127405442416114, userId=be6531934024, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f21013993802, moduleTitle=NEJM：Ivosidenib治疗IDH1突变型AML疗效喜人, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f21013993802)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715482, encodeId=ba951e1548295, content=<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>, objectTitle=Leukemia：维生素C能诱导IDH1突变的急性髓系白血病的表观遗传修饰, objectType=article, longId=127599, objectId=099312e5996f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=099312e5996f, replyNumber=0, likeNumber=94, createdTime=2018-07-29, rootId=0, userName=ms6127405442416114, userId=be6531934024, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=099312e5996f, moduleTitle=Leukemia：维生素C能诱导IDH1突变的急性髓系白血病的表观遗传修饰, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=099312e5996f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715480, encodeId=922e1e1548054, content=<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>, objectTitle=Oncotarget：“多子丸”克罗米芬靶向突变IDH1抗癌, objectType=article, longId=98167, objectId=6d5e9816e82, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d5e9816e82, replyNumber=0, likeNumber=114, createdTime=2018-01-15, rootId=0, userName=ms6127405442416114, userId=be6531934024, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d5e9816e82, moduleTitle=Oncotarget：“多子丸”克罗米芬靶向突变IDH1抗癌, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6d5e9816e82)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

IDH1

2020-05-29

williamhill asia 管理员 (审核中...)

前往app查看评论内容

#IDH1# #去甲基化酶# #2-羟基戊二酸#

2024-07-13发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

全文收起高达50%的#胆管癌#可能是#分子靶向治疗#的潜在受益者。几项规模较小的临床试验显示了二线以上靶向治疗的潜力。比如#FGFR2#、#NTRK#、#IDH1#、#BRAF#、#HER2#等#基因突变#。以及#微卫星不稳定性#MSI的情况，这些相关指标的检测也将会为胆管癌患者的精准治疗打下相应的治疗基础。事实上，其它#肿瘤#也是一样的，各个不同的肿瘤都应该按这个思路研究一遍，对于象#三阴性乳腺癌#，#小细胞肺癌#，#卵巢癌#，同样如此，williamhill asia 各位会员们，你们如果有兴趣，要尽快研究，这是一个很好的方向，当然，也可以申请#国家自然科学基金##国自然基金#

真实数据，高达50%的胆管癌是分子靶向治疗的潜在受益者，有机会活得更好、更长！

2023-10-10发表于上海

ms6127405442416114 (审核中...)

前往app查看评论内容

#IDH1#

NEJM：艾伏尼布联合阿扎胞苷治疗IDH1突变AML的3期研究结果公布，患者获益显著

2023-02-21

ms6127405442416114 (审核中...)

前往app查看评论内容

#IDH1#

Neurology病例：Ollier病中经组织病理学证实的颅内内生软骨瘤/低级别软骨肉瘤和IDH1突变的弥漫性胶质瘤

2022-09-03

ms6127405442416114 (审核中...)

前往app查看评论内容

#IDH1#

Clin Cancer Res：维奈托克+阿扎胞苷可显著改善IDH1/2突变AML患者的预后

2022-10-13

ms6127405442416114 (审核中...)

前往app查看评论内容

#IDH1#

Clin Cancer Res：突变型IDH1/2双重抑制剂Vorasidenib治疗复发/进展胶质瘤的效果

2022-06-19

ms6127405442416114 (审核中...)

前往app查看评论内容

#IDH1#

PNAS：雷公藤变成为靶向药物？有望用于治疗IDH1突变的癌症

2021-05-10

ms6127405442416114 (审核中...)

前往app查看评论内容

#IDH1#

Clin Cancer Res：突变型IDH1/2双重抑制剂Vorasidenib治疗复发/进展胶质瘤的效果

2022-06-27

ms6127405442416114 (审核中...)

前往app查看评论内容

#IDH1#

JAMA Oncol：Ivosidenib (AG-120)可改善经治IDH1突变肝内胆管细胞癌患者的总生存：III期ClarIDHy研究最终OS分析结果

2021-10-08

ms6127405442416114 (审核中...)

前往app查看评论内容

#IDH1#

Blood：IDH1突变通过干扰血红素合成和红细胞生成导致髓系发育不良

2021-09-18

ms6127405442416114 (审核中...)

前往app查看评论内容

#IDH1#

FDA批准抗肿瘤药物IDH1抑制剂HH2301临床试验

2020-08-14

ms6127405442416114 (审核中...)

前往app查看评论内容

#IDH1#

Radiology：IDH1突变胶质瘤在超高分辨率3D MR波谱下会有什么发现？

2020-10-16

ms6127405442416114 (审核中...)

前往app查看评论内容

#IDH1#

Lancet Oncol：Ivosidenib显著改善晚期mIDH1胆管癌患者的生存率

2021-10-17

ms6127405442416114 (审核中...)

前往app查看评论内容

#IDH1#

Blood：DNMT3A和IDH1/2基因突变携带诱导血液恶性肿瘤的发生！

2020-11-24

ms6127405442416114 (审核中...)

前往app查看评论内容

#IDH1#

Cell Death & Disease：前列腺癌中PAX5能够诱导IDH1-AS1上调来促进肿瘤的生长

2020-06-22

ms6127405442416114 (审核中...)

前往app查看评论内容

#IDH1#

2019年ESMO：Ivosidenib显著改善晚期mIDH1胆管癌患者的生存率

2020-04-09

ms6127405442416114 (审核中...)

前往app查看评论内容

#IDH1#

FDA批准**IDH1抑制剂用于治疗复发或难治性AML

2019-06-15

ms6127405442416114 (审核中...)

前往app查看评论内容

#IDH1#

NEJM：Ivosidenib治疗IDH1突变型AML疗效喜人

2018-10-06

ms6127405442416114 (审核中...)

前往app查看评论内容

#IDH1#

Leukemia：维生素C能诱导IDH1突变的急性髓系白血病的表观遗传修饰

2018-07-29

ms6127405442416114 (审核中...)

前往app查看评论内容

#IDH1#

Oncotarget：“多子丸”克罗米芬靶向突变IDH1抗癌

2018-01-15

科室
- - 订阅+
  - 更多科室
工具
服务